$ASEI (American Science & Engineering Inc.)

$ASEI {{ '2016-06-22T14:50:42+0000' | timeago}} • Announcement

$ASEI said it agreed to be acquired by $OSIS for $37 per common share in an all-cash transaction, for a total transaction value of about $269MM. The transaction consideration represents a premium of about 25% based on volume-weighted average closing stock price for 90 days up to and including June 20.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$TBPH {{ '2017-07-20T12:32:48+0000' | timeago}} • Announcement

$TBPH and $MYL announced positive results from a 12-month Phase 3 safety study of revefenacin in patients with chronic obstructive pulmonary disease (COPD). The study of 1,055 patients with COPD demonstrated that revefenacin was generally well-tolerated, and no new safety issues were identified.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$MYL {{ '2017-07-14T12:05:52+0000' | timeago}} • Announcement

Pharma firm $MYL said the FDA Oncologic Drugs Advisory Committee has recommended approval of the biosimilar trastuzumab developed by Mylan along with India-based Biocon Ltd. for  treatment of breast cancer. The committee determined no clinically meaningful differences exist between the biosimilar product and cancer drug Herceptin.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$CACI {{ '2017-06-21T21:32:23+0000' | timeago}} • Announcement

$CACI is reiterating its FY17 guidance. The company expects revenue of $4.2-4.3Bil. Net income is expected to be $157-163MM while diluted EPS is expected to be $6.25-6.49.

$CACI {{ '2017-06-21T21:32:00+0000' | timeago}} • Announcement

$CACI has issued its FY18 guidance. Revenue is expected to be $4.3-4.5Bil. Net income is expected to be $165-173MM and diluted EPS is expected to be $6.52-6.84. $CACI expects gross profit margin to be 32-33% while operating cash flow is expected to be greater than $280MM. Capex is expected to be $35-40MM.

$HOLX {{ '2017-06-20T15:15:28+0000' | timeago}} • Announcement

$HOLX has obtained FDA clearance to market the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system. The test will be commercially available in the 50 United States, US territories and Puerto Rico.

$ABT {{ '2017-06-16T10:42:39+0000' | timeago}} • Announcement

$ABT announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific.

$HOLX {{ '2017-06-15T13:06:41+0000' | timeago}} • Announcement

$HOLX said that the FDA has granted an expanded clearance for Cynosure's body contouring product, SculpSure, to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen and love handles.

$LLY {{ '2017-06-14T08:45:38+0000' | timeago}} • Announcement

Pharma firms $LLY and $INCY will present data from studies conducted on Olumiant, indicated for inflammatory and autoimmune diseases, at the Annual European Congress of Rheumatology being held in Madrid from June 14 to 17, 2017. Six abstracts evaluating Taltz, indicated for the treatment of psoriatic arthritis, will also be presented at the meet.

$PLXS {{ '2017-06-12T21:36:35+0000' | timeago}} • Announcement

$PLXS announced the expansion of their Engineering Solutions business. Plexus has increased capacity of the Neenah Design Center by moving to a new office space located in downtown Neenah, Wisconsin and opening a new Engineering Solutions Design Center in Guadalajara, Mexico.

Recent Transcripts

BAH (Booz Allen Hamilton Holding Corporation)
Monday, May 22 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
MYL (Mylan N.V.)
Wednesday, May 10 2017 - 2:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
KTOS (Kratos Defense & Security Solutions, Inc.)
Thursday, May 4 2017 - 9:00pm
UEIC (Universal Electronics Inc.)
Thursday, May 4 2017 - 8:30pm
ICFI (ICF International Inc.)
Thursday, May 4 2017 - 8:15pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
CACI (CACI International Inc.)
Thursday, May 4 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
LLL (L-3 Communications Holdings Inc.)
Thursday, April 27 2017 - 3:00pm
NOC (Northrop Grumman Corporation)
Wednesday, April 26 2017 - 4:00pm
PLXS (Plexus Corp.)
Thursday, April 20 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, March 14 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Tuesday, February 28 2017 - 12:30pm
KTOS (Kratos Defense & Security Solutions, Inc.)
Monday, February 27 2017 - 10:30pm
ICFI (ICF International Inc.)
Monday, February 27 2017 - 10:00pm

AlphaGraphics you may like